Inhibition of the angiotensin II type 1 receptor by TCV-116: Quantitation by in vitro autoradiography

Japanese Journal of Pharmacology

Volumn 79, Issue 2, 1999, Pages 131-139

  Song, Keifu ^a   Kanehara, Hironori ^a   Takai, Shinji ^a   Shiota, Naotaka ^a   Wada, Takeo ^b   Inada, Yoshiyuki ^b   Miyazaki, Mizuo ^a  

^a OSAKA MEDICAL COLLEGE   (Japan)

^b TAKEDA PHARMACEUTICAL COMPANY LIMITED   (Japan)

Author keywords

Angiotensin II receptor; Blood brain barrier; CV 11974; TCV 116

Indexed keywords

1 (4 DIMETHYLAMINO 3 METHYLBENZYL) 5 DIPHENYLACETYL 4,5,6,7 TETRAHYDRO 1H IMIDAZO[4,5 C]PYRIDINE 6 CARBOXYLIC ACID; ANGIOTENSIN; ANGIOTENSIN 1 RECEPTOR; ANGIOTENSIN 2 RECEPTOR; ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; CANDESARTAN HEXETIL; LOSARTAN;

ADRENAL CORTEX; ADRENAL MEDULLA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTERIOR HYPOTHALAMUS; ARTICLE; BLOOD BRAIN BARRIER; BRAIN; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG RECEPTOR BINDING; DRUG SPECIFICITY; HEART; INFERIOR OLIVE; KIDNEY; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; RADIORECEPTOR ASSAY; RAT; RECEPTOR BINDING; RECEPTOR DENSITY; SOLITARY TRACT NUCLEUS; TESTIS; THORACIC AORTA;

EID: 0032996991     PISSN: 00215198     EISSN: None     Source Type: Journal    
DOI: 10.1254/jjp.79.131     Document Type: Article

References (28)

1. Jackson EK and Garrison JC: Renin and angiotensin. In The Pharmacological Basis of Therapeutics (9th Edition), Edited by Hardman JG, Limbird LE, Molinoff PB, Ruddon RW and Gilman AG, pp 733-758, McGraw-Hill, New York (1996)
2. Whitbread S, Mele M, Kamber B and de Gasparo M: Preliminary biochemical characterization of two angiotensin II receptor subtypes. Biochem Biophys Res Commun 163, 284-291 (1989)
3. Chiu AT, Herblin WF, McCall DE, Ardecky RJ, Carini DJ, Duncia JV, Pease LJ, Wong PC, Wexler RR, Johnson AL and Timmermans PBMWM: Identification of angiotensin II receptor subtypes. Biochem Biophys Res Commun 165, 196-203 (1989)
4. Bumpus FM, Catt KJ, Chiu AT, de Gasparo M, Goodfriend T, Husain A, Peach MJ, Tayler DG Jr and Timmermans PBMWM: Nomenclature for angiotensin receptors. A report of the nomenclature committee of the council for high blood pressure research. Hypertension 17, 720-721 (1991)
5. Timmermans PBMWM, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RR, Saye AM and Smith RD: Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol Rev 45, 205-251 (1993)
6. Shibouta Y, Inada Y, Ojima M, Wada T, Noda M, Sanada T, Kubo K, Kohara Y, Naka T and Nishikawa K: Pharmacological profile of a highly potent and long-acting angiotensin II receptor antagonist, 2-ethoxy-1-[[2′-(1H-tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole- 7-carboxylic acid (CV-11974), and its prodrug, (±)-1-(cyclohexyloxycarbonyloxy)-ethyl-2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazol-7-carboxylate (TCV-116). J Pharmacol Exp Ther 266, 114-120 (1993)
7. Kim S, Ohta K, Hamaguchi A, Omura T, Yukimura T, Miura K, Inada Y, Wada T, Ishimura Y, Chatani F and Iwao H: Role of angiotensin II in renal injury of deoxycorticosterone acetate-salt hypertensinve rats. Hypertension 24, 195-204 (1994)
8. Song K, Zhuo J, Allen AM, Paxinos G and Mendelsohn FAO: Mapping of angiotensin II receptor subtype heterogeneity in rat brain. J Comp Neurol 316, 467-484 (1992)
9. Kondo T, Ogihara K, Katoh Y, Yoshida K, Yoshimura Y, Motohashi M and Tanayama K: Metabolic fate of TCV-116, a new angiotensin II receptor antagonist, in rats and dogs. Jpn Pharmacol Ther 24, Suppl S915-S943 (1996)
10. Song K, Zhuo J and Mendelsohn FAO: Access of peripherally administered DuP 753 to rat brain angiotensin II receptors. Br J Pharmacol 104, 771-772 (1992)
11. 1 angiotensin II receptors in rat brain, kidney and adrenal glands demonstrated by in vitro autoradiography. Clin Exp Pharmacol Physiol 21, 557-567 (1994)
12. Mackenley MJ, Allen AM, Clevers J, Denton DA and Mendelsohn FAO: Autoradiographic localization of angiotensin II receptors in sheep brain. Brain Res 375, 373-376 (1985)
13. Inada Y, Wada T, Shibouta Y, Ojima M, Sanada T, Ohtsuki K, Itoh K, Kubo K, Kohara Y, Naka T and Nishikawa K: Anti-hypertensive effects of a highly potent and long-acting angiotensin II subtype-1 receptor antagonist, (±)-1-(cyclohexyloxy-carbonyloxy)-ethyl-2-ethoxy-1-[[2′-(1H- tetrazol-5-yl)biphenyl-4-yl]methyl]-1H-benzimidazole-7-carboxylate (TCV-116), in various hypertensive rats. J Pharmacol Exp Ther 268, 1540-1547 (1994)
14. Dufau ML, Ulisse S, Khanum A, Buczko E, Kitamura M, Fabbti A and Namiki M: LH action in the Leydig cell: Modulation by angiotensin II and corticotrophin releasing hormone, and regulation of P450 17α mRNA. J Steroid Biochem 34, 205-217 (1989)
15. Kanehara H, Song K, Hirai K, Ueda H, Shiota N, Azuma H, Katsuoka Y, Miyazaki H and Miyazaki M: Involvement of angiotensin II receptor subtypes during testicular development in rats. Int J Andrology 21, 186-195 (1998)
16. Vitale R, Fawcett DW and Dym M: The normal development of the blood-testis barrier and the effects of clomiphene and estrogen treatment. Anat Rec 176, 333-334 (1973)
17. Phillips PI: Functions of angiotensin in the central nervous system. Annu Rev Physiol 48 413-435 (1987)
18. Noback CR and Demarest RJ: The Human Nervous System: Basic Principles of Neurobiology, pp 75-78, McGraw-Hill, New York (1981)
19. 125I]-angiotensin II binding sites in the rat brain. Eur J Pharmacol 187, 123-126 (1990)
20. Sakaguchi K, Chai S-Y, Jackson B, Johnston CI and Mendelsohn FAO: Differential angiotensin-converting enzyme inhibition in brain after oral administration of perindopril demonstrated by quantitative in vitro autoradiography. Neuroendocrinology 48, 223-228 (1988)
21. Sakaguchi K, Chai S-Y, Jackson B, Johnston CI and Mendelsohn FAO: Inhibition of tissue angiotensin converting enzyme: Quantitation by autoradiography. Hypertension 11, 230-238 (1988)
22. Takai S, Song K, Tanaka T, Okunishi H and Miyazaki M: Antinociceptive effects of angiotensin-converting enzyme inhibitors and an angiotensin II receptor antagonist in mice. Life Sci 59, PL331-PL336 (1996)
23. Wong PC, Price WA, Chiu AT, Smith RD and Timmermans PBMWM: Nonpeptide angiotensin II receptor antagonists. VIII. Characterization of functional antagonism displayed by DuP753, an orally active antihypertensive agent. J Pharmacol Exp Ther 252, 719-725 (1990)
24. Bui JD, Kimura B and Phillips MI: Losartan potassium, a nonpeptide antagonist of angiotensin II, chronically administered p.o. does not readily cross the blood brain barrier. Eur J Pharmacol 219, 147-151 (1992)
25. DePasquale MJ, Fossa AA, Holt WF and Mangiapene ML: Central DuP753 does not lower blood pressure in spontaneously hypertensive rats. Hypertension 19, 668-677 (1992)
26. 2 receptor antagonist WL 19. Eur J Pharmacol 211, 113-116 (1992)
27. Li Z, Bains JS and Ferguson AV: Functional evidence that the angiotensin antagonist losartan crosses the blood-brain barrier in the rat. Brain Res Bull 30, 33-39 (1992)
28. Dwaskin LP, Jewell AL and Cassis LA: DuP753: a nonpeptide angiotensin II-1 receptor antagonist, alters dopaminergic function in the rat striatum. Naunyn Schmiedebergs Arch Pharmacol 345, 153-159 (1992)